Literature DB >> 17060800

Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF).

Barrett Katz1, Mauro Goldbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17060800     DOI： 10.1097/01.iio.0000212130.91136.31

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN： 0020-8167


× No keyword cloud information.
  4 in total

1.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

Authors:  Justin P Dassie; Xiu-Ying Liu; Gregory S Thomas; Ryan M Whitaker; Kristina W Thiel; Katie R Stockdale; David K Meyerholz; Anton P McCaffrey; James O McNamara; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2009-08-23       Impact factor: 54.908

Review 2.  Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology.

Authors:  Yuhua Weng; Qianqian Huang; Chunhui Li; Yongfeng Yang; Xiaoxia Wang; Jie Yu; Yuanyu Huang; Xing-Jie Liang
Journal:  Mol Ther Nucleic Acids       Date:  2019-12-17       Impact factor: 8.886

3.  Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.

Authors:  Hwa Yeon Jeong; Hyeri Kim; Myunghwa Lee; Jinju Hong; Joo Han Lee; Jeonghyeon Kim; Moon Jung Choi; Yong Serk Park; Sung-Chun Kim
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

4.  Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.

Authors:  Marcelo L Occhiutto; Fatima R Freitas; Raul C Maranhao; Vital P Costa
Journal:  Pharmaceutics       Date:  2012-05-14       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.